Showing results (551-560 of 654) with videos related to

Sort By:
Pageof 66
Clinical Chemistry|September 20, 2011
Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetesClaudia Cangemi, Vibe Skov, Michael Kjaer Poulsen, et al.
Nature Medicine|September 20, 2024
Lipid profiling identifies modifiable signatures of cardiometabolic risk in children and adolescents with obesityYun Huang, Karolina Sulek, Sara E Stinson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 10, 2020
A New Panel-Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse PopulationLesley A Inker, Sara J Couture, Hocine Tighiouart, et al.
Journal of the American Society of Nephrology : JASN|October 25, 2023
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD TrialsRobert A Fletcher, Niels Jongs, Glenn M Chertow, et al.
Journal of the American Society of Nephrology : JASN|March 29, 2026
Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and FinerenoneRajiv Agarwal, Ricardo Correa-Rotter, Sankar D Navaneethan, et al.
Plos One|October 27, 2010
Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathyAlaa Alkhalaf, Petra Zürbig, Stephan J L Bakker, et al.
Diabetologia|April 21, 2022
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trialSimke W Waijer, Priya Vart, David Z I Cherney, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 30, 2020
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney FoundationKatherine R Tuttle, Frank C Brosius, Matthew A Cavender, et al.
Nature Medicine|June 24, 2024
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trialJohannes F E Mann, Peter Rossing, George Bakris, et al.
Diabetes|October 27, 2020
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney FoundationKatherine R Tuttle, Frank C Brosius, Matthew A Cavender, et al.
Pageof 66